Vor Ort
Merkzettel Warenkorb
  • Produktbild: Early Markers in Parkinson’s and Alzheimer’s Diseases
  • Produktbild: Early Markers in Parkinson’s and Alzheimer’s Diseases
Band 1

Early Markers in Parkinson’s and Alzheimer’s Diseases

Aus der Reihe New Vistas in Drug Research

49,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

09.01.2012

Abbildungen

XX, 310 p.

Herausgeber

Philippe Dostert + weitere

Verlag

Springer Wien

Seitenzahl

310

Maße (L/B/H)

22,9/15,2/1,9 cm

Gewicht

488 g

Auflage

Softcover reprint of the original 1st edition 1990

Sprache

Englisch

ISBN

978-3-7091-9100-2

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

09.01.2012

Abbildungen

XX, 310 p.

Herausgeber

Verlag

Springer Wien

Seitenzahl

310

Maße (L/B/H)

22,9/15,2/1,9 cm

Gewicht

488 g

Auflage

Softcover reprint of the original 1st edition 1990

Sprache

Englisch

ISBN

978-3-7091-9100-2

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Early Markers in Parkinson’s and Alzheimer’s Diseases
  • Produktbild: Early Markers in Parkinson’s and Alzheimer’s Diseases
  • Early markers in Parkinson’s disease.- Early markers in Parkinson’s disease.- Differential diagnosis of Parkinson’s disease.- The premorbid personality of patients with Parkinson’s disease.- An antibody in the CSF of Parkinson’s disease patients: summary of data and potential role as a diagnostic marker.- Contribution of motor performance tests to the early diagnosis of Parkinson’s disease.- Electrophysiological methods in the early diagnosis of Parkinson’s disease.- Characterization of Parkinson’s disease using positron emission tomography.- Dopamine beta-hydroxylase and beta 2-microglobulin in cerebrospinal fluid: early markers in Parkinson’s disease.- Urinary dopamine sulfate conjugates in Parkinson’s disease.- Salsolinol and the early detection of Parkinson’s disease.- MR imaging of putamenal iron predicts response to dopaminergic therapy in parkinsonian patients.- The neurotoxic component in Parkinson’s disease may involve iron-melanin interaction and lipid peroxidation in the substantia nigra.- Round table on Parkinson’s disease.- Early markers in Alzheimer’s disease.- The need for early markers in Alzheimer’s disease.- Descriptive and analytic epidemiology of Alzheimer’s disease.- Differential diagnosis of early Alzheimer’s disease.- Down syndrome: a model for the study of Alzheimer’s disease and aging.- PET scanning for the detection of Alzheimer’s disease.- Reference-free evaluation of auditory evoked potentials—P300 in aging and dementia.- Enzymes and glial cells in brain damage and neurodegenerative diseases.- Senile dementia of Alzheimer’s type and Parkinson’s disease: neurochemical overlaps and specific differences.- Changes in brain energy metabolism and the early detection of Alzheimer’s disease.- Cholinemetabolism in Alzheimer’s disease: hints as to possible markers.- The presence of antibrain antibodies in the CSF of some Alzheimer disease patients: correlation with CSF parameters.- Increased monoamine oxidase activity and vitamin B-12 deficiency in dementia disorders.- Round table on Alzheimer’s disease.- Closing remarks.